Acumen Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Acumen Pharmaceuticals's estimated annual revenue is currently $3.8M per year.
- Acumen Pharmaceuticals's estimated revenue per employee is $52,315
- Acumen Pharmaceuticals's current valuation is $217.7M. (January 2022)
Employee Data
- Acumen Pharmaceuticals has 73 Employees.
- Acumen Pharmaceuticals grew their employee count by 30% last year.
Acumen Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate VP, Finance & Corporate Treasurer | Reveal Email/Phone |
2 | Associate VP, Business Development | Reveal Email/Phone |
3 | VP, Head CMC | Reveal Email/Phone |
4 | EVP, Head HR | Reveal Email/Phone |
5 | VP, Head Regulatory Affairs | Reveal Email/Phone |
6 | VP, Head Investor Relations | Reveal Email/Phone |
7 | VP, Finance & Accounting/Corporate Controller | Reveal Email/Phone |
8 | VP, Drug Safety & Pharmacovigilance | Reveal Email/Phone |
9 | Chief Operating Officer | Reveal Email/Phone |
10 | Director, Data Management | Reveal Email/Phone |
Acumen Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $15.9M | 79 | 25% | $210M | N/A |
#2 | $30.2M | 182 | N/A | N/A | N/A |
#3 | $6.6M | 33 | 6% | N/A | N/A |
#4 | $7.8M | 39 | -39% | N/A | N/A |
#5 | $4.8M | 24 | 4% | N/A | N/A |
#6 | $12.5M | 62 | 7% | N/A | N/A |
#7 | $22.1M | 110 | 7% | N/A | N/A |
#8 | $11.7M | 58 | -9% | N/A | N/A |
#9 | $5.8M | 29 | -12% | N/A | N/A |
#10 | $42.4M | 211 | N/A | N/A | N/A |
What Is Acumen Pharmaceuticals?
Acumen is forging a new path towards safe and effective treatments for Alzheimer's disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.
keywords:N/A
N/A
Total Funding
73
Number of Employees
$3.8M
Revenue (est)
30%
Employee Growth %
$217.7M
Valuation
N/A
Accelerator
Acumen Pharmaceuticals News
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Up 47.0% in March. Posted by admin on Apr 17th, 2022. Share on Twitter Share on Facebook Share on...
Acumen is focused on the development of novel targeted therapeutics for Alzheimer's disease, which has received significant attention over the...
and CARMEL, Ind., March 28, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company...
Other Companies in Charlottesville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.5M | 75 | 6% | N/A |
#2 | $10.1M | 75 | 4% | N/A |
#3 | $15.3M | 75 | -17% | N/A |
#4 | $9.8M | 75 | N/A | N/A |
#5 | $6.8M | 75 | -1% | N/A |